Evidence map›Paper›PMID 42671525›Full record

ArticleProbiotics and antimicrobial proteins2026

Improving the Antimicrobial Activity of an Amyloidogenic Aβ Peptide Through Additional Fragments.

Jinli Lan, Yujiao Pan, Min Zhu, Kaiqin Ye, Yazhong Xiao, Xuecheng Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jinli LanSchool of Life Sciences and Medical Engineering, Anhui University, Hefei, Anhui, 230601, P.R. China.
Yujiao PanSchool of Life Sciences and Medical Engineering, Anhui University, Hefei, Anhui, 230601, P.R. China.
Min ZhuSchool of Life Sciences and Medical Engineering, Anhui University, Hefei, Anhui, 230601, P.R. China.
Kaiqin YeInstitute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, Anhui, P.R. China.
Yazhong XiaoSchool of Life Sciences and Medical Engineering, Anhui University, Hefei, Anhui, 230601, P.R. China.
Xuecheng ZhangSchool of Life Sciences and Medical Engineering, Anhui University, Hefei, Anhui, 230601, P.R. China. turenzh@ahu.edu.cn.

Funding

National Natural Science Foundation of China 31470775
6 · The paper itself

Abstract

Given the similarities of action mechanism between amyloidogenic peptides (e.g. Aβ) and antimicrobial peptides (AMPs), we rationally engineered an amyloidogenic Aβ peptide to improve its antimicrobial activity: the aggregation-prone fragment was reverse-repeated to increase antimicrobial activity; poly-arginine (R) was flanked to both ends of the repeated fragments to enhance membrane interaction and inhibit amyloidogenesis; a β-turn fragment (DPDG/YNGK) was inserted between the repeated fragments to inhibit amyloidogenesis. Antimicrobial assays demonstrated that the designed peptides exhibited significantly enhanced antimicrobial activity. Among the designed peptides, Aβ-6R-YNGK, Aβ-6R-YNGK-r, Aβ-10R-YNGK, and Aβ-10R-YNGK-r exhibited potent antimicrobial activity, particularly against Staphylococcus epidermidis with MICs of 5, 5, 5, and 1 µM, respectively. Moreover, at 20 µM, these peptides showed significant anticancer activity and low cytotoxicity, reducing U937 human lymphoma cell viability to below 30% while maintaining over 80% viability of human microglial HMC3 cell. Our rational design approach provides a novel strategy for engineering antimicrobial peptide. The designed antimicrobial peptides Aβ-6R-YNGK, Aβ-6R-YNGK-r, Aβ-10R-YNGK, and Aβ-10R-YNGK-r hold promise as a new class of antimicrobial/cancer agents.

Indexed as

Amyloidogenesis inhibitionAmyloidogenic peptideAnticancer activityAntimicrobial peptideAβRational design

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.